Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Miromatrix Medical Inc.

This article was originally published in Start Up

Executive Summary

Regenerative medicine start-up Miromatrix Medical is working to commercialize a technology known as perfusion decellularization. Its proprietary, patent-protected technology involves the decellularization of any vascularized tissue, up to and including whole organs, leaving behind a completely preserved native scaffold (matrix) that retains the original architecture, mechanical properties and vascular network of the tissue or organ. This scaffold can then be repopulated with vascular- and organ-specific regenerative cells and, under controlled conditions in a bioreactor, a biocompatible, functioning organ or tissue is created.
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092042

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel